Excellence in Single Domain Biotherapeutics
Isogenica develops LlamdA® VHH: highly versatile small format antibodies which we use to construct next generation biotherapeutics for the treatment of cancer, inflammation and other serious diseases.
LlamdA® VHH can be assembled to create bispecific and multi-specific biotherapeutics, or used to achieve targeted drug delivery as components of ADCs and cell and gene therapies including CAR-Ts.
Isogenica’s partnerships with global biopharmaceutical companies have resulted in a deep pipeline including one clinical Phase II asset and eleven partnered pre-clinical and discovery programs.
Isogenica works with partners through collaborative research and commercial licenses to further develop proprietary LlamdA® VHH or to discover novel LlamdA® VHH as direct therapeutics and targeting agents.
Isogenica’s LlamdA® VHH synthetic libraries are displayed in phage or in the company’s proprietary CIS Display technology.
These are combined to provide a powerful discovery engine for single domain biotherapeutics.
News & Events
Isogenica has made two leadership appointments to extend and accelerate its partnerships and pipeline of therapeutic assets and provide a strong...
Isogenica multi-target, multi-year collaboration and license agreement with BioNTech SEIsogenica has entered into a multi-target, multi-year...
Careers at Isogenica
A career at Isogenica provides an opportunity to lead, execute or support the commercial development of next generation biotherapeutics.